Ana Triguero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Triguero has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Martínez
Hospital Clínic Barcelona
11 shared publications - Catherine J. Lee
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
11 shared publications - Clara García-Calderón
Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Junta de Andalucía, Consejo Superior de Investigaciones Científicas), Seville, Spain
11 shared publications - Eduardo Rodríguez-Arbolí
Department of Hematology, Hospital Universitario Virgen del Rocio
11 shared publications - José Antonio Pérez-Simón
Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, (IBIS, CSIC) Universidad de Sevilla, Sevilla, Spain
11 shared publications - Lucía López-Corral
Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
11 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n=11 R, n=4 NR) (B), unswitched memory B cells cells (C1D1: n=12 R, n=5 NR; C2D1: n=12 R, n=4 NR; C4D1: n=11 R, n=3 NR) (C) and switched memory B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=4 NR) (D). E) Fold change in CD268 (BAFF) expression on B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=3 NR). MFI normalised ratios were used for expression quantification. MFI, median fluorescence intensity; n.s., non-statistically significant.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n=11 R, n=4 NR) (B), unswitched memory B cells cells (C1D1: n=12 R, n=5 NR; C2D1: n=12 R, n=4 NR; C4D1: n=11 R, n=3 NR) (C) and switched memory B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=4 NR) (D). E) Fold change in CD268 (BAFF) expression on B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=3 NR). MFI normalised ratios were used for expression quantification. MFI, median fluorescence intensity; n.s., non-statistically significant.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubation with ionomycin (0.91 µg/mL) and PMA (20 µg/mL). Brefeldin A (10 μg/mL) was added in both conditions. Differences between serial evaluations on day 1 of cycles 1, 2 and 4 were examined in skin/joints scGVHD responder (C1D1: n=11; C2D1: n=13; C4D1: n=12) and non-responder patients (C1D1: n=7; C2D1: n=7; C4D1: n=5). n.s., non-statistically significant. *Omnibus Friedman test. In post-hoc tests, only a statistically significant difference between visits C2D1 and C4D1 was detected (p=0.011).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubation with ionomycin (0.91 µg/mL) and PMA (20 µg/mL). Brefeldin A (10 μg/mL) was added in both conditions. Differences between serial evaluations on day 1 of cycles 1, 2 and 4 were examined in skin/joints scGVHD responder (C1D1: n=11; C2D1: n=13; C4D1: n=12) and non-responder patients (C1D1: n=7; C2D1: n=7; C4D1: n=5). n.s., non-statistically significant. *Omnibus Friedman test. In post-hoc tests, only a statistically significant difference between visits C2D1 and C4D1 was detected (p=0.011).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 nM (pERK and p38 analyses), IL-2 50 ng/mL (pSTAT5 analysis) or IL-6 20 ng/mL (pSTAT3 analysis) in the CD4+ and CD8+ T-cell subsets. Differences between post-activation/resting MFI ratios were examined in skin/joints scGVHD responder (C1D1: n=13; C2D1: n=13; C4D1: n=12) and non-responder (C1D1: n=7; C2D1: n=7; C4D1: n=5) patients in serial evaluations on day 1 of cycles 1, 2 and 4. MFI, median fluorescence intensity; n.s., non-statistically significant. *Omnibus Friedman test. No differences were detected in post-hoc tests.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 nM (pERK and p38 analyses), IL-2 50 ng/mL (pSTAT5 analysis) or IL-6 20 ng/mL (pSTAT3 analysis) in the CD4+ and CD8+ T-cell subsets. Differences between post-activation/resting MFI ratios were examined in skin/joints scGVHD responder (C1D1: n=13; C2D1: n=13; C4D1: n=12) and non-responder (C1D1: n=7; C2D1: n=7; C4D1: n=5) patients in serial evaluations on day 1 of cycles 1, 2 and 4. MFI, median fluorescence intensity; n.s., non-statistically significant. *Omnibus Friedman test. No differences were detected in post-hoc tests.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the immunophenotypic analyses
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the immunophenotypic analyses
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Purpose:Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated glasdegib, a smoothened antagonist, as a novel therapeutic agent in refractory scGVHD.Patients and Methods:Adult patients with active scGVHD after ≥1 (FHD) or ≥2 (GETH-TC) lines of therapy were enrolled. Primary endpoints were dose-limiting toxicity (DLT) and MTD in the GETH-TC trial, and safety and tolerability measures in the FHD trial. Glasdegib was administered once daily in 28-day cycles. Responses were scored per 2014 NIH cGVHD criteria. Correlative studies were performed to evaluate the role of fibroblast-independent immune mechanisms on clinical activity.Results:Twenty (GETH-TC) and 15 (FHD) patients were recruited. Treatment-emergent grade (G) ≥2 adverse events (AE) in the GETH-TC trial included muscle cramps (85%), alopecia (50%), and dysgeusia (35%). Two patients experienced a DLT (G3 muscle cramps), and the MTD was established at 50 mg. G3 muscle cramps were the most frequently reported AE (33%) in the FHD trial. At 12-months, the skin/joint scGVHD overall response rate was 65% (all partial responses) in the GETH-TC trial and 47% (6 partial responses, 1 complete response) in the FHD cohort. No immune correlates of response were identified.Conclusions:Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Purpose:Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated glasdegib, a smoothened antagonist, as a novel therapeutic agent in refractory scGVHD.Patients and Methods:Adult patients with active scGVHD after ≥1 (FHD) or ≥2 (GETH-TC) lines of therapy were enrolled. Primary endpoints were dose-limiting toxicity (DLT) and MTD in the GETH-TC trial, and safety and tolerability measures in the FHD trial. Glasdegib was administered once daily in 28-day cycles. Responses were scored per 2014 NIH cGVHD criteria. Correlative studies were performed to evaluate the role of fibroblast-independent immune mechanisms on clinical activity.Results:Twenty (GETH-TC) and 15 (FHD) patients were recruited. Treatment-emergent grade (G) ≥2 adverse events (AE) in the GETH-TC trial included muscle cramps (85%), alopecia (50%), and dysgeusia (35%). Two patients experienced a DLT (G3 muscle cramps), and the MTD was established at 50 mg. G3 muscle cramps were the most frequently reported AE (33%) in the FHD trial. At 12-months, the skin/joint scGVHD overall response rate was 65% (all partial responses) in the GETH-TC trial and 47% (6 partial responses, 1 complete response) in the FHD cohort. No immune correlates of response were identified.Conclusions:Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.
- Open Access
- 31 January 2025
- Published by Wiley in HemaSphere
- Vol. 9 (2) , e70072
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
- 31 January 2025
- Published by Wiley in HemaSphere
- Vol. 9 (2) , e70072
Open AccessCytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry